This $1,000,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of Helixbind's RAPID/BSI, an automated, culture-free system for the rapid identification of bloodstream infections directly from blood samples. The project aims to complete verification and validation activities to prepare for FDA regulatory clearance of this breakthrough diagnostic technology....
The University of Maryland, College Park was awarded a $490,093 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid antibiotic susceptibility testing platform. The technology aims to isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75 minutes from initial blood draw. This will be...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
This Project Grant award of $298,646 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a rapid diagnostic test for sepsis-causing pathogens at Anvil Diagnostics Inc., a minority-owned small business in Cambridge, MA. The proposed DNA-based technology aims to comprehensively identify and quantify a broad range of pathogens in plasma samples using digital PCR hardware, providing results within 4 hours from small...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,170 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Latde Diagnostics Corp., a woman-owned small business, to develop a rapid, equitable, lateral flow-based antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal of this Phase I project is to demonstrate the feasibility of the Metabolic Amino Acid Phenotyping (MAAP) test kit to provide rapid AST...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $781,129 to The Regents of the University of California, San Francisco (UCSF) to conduct a prospective, multicenter cohort study of 400 critically ill children with acute respiratory failure. The goal is to validate and extend an integrated host-microbe metagenomic diagnostic tool developed by the research team. This...
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a rapid point-of-care antimicrobial susceptibility testing (AST) kit by Giant Biosystems Inc., a small business located in Pasadena, CA. The goal is to create an AST platform that can provide actionable results within 6-9 hours from sample collection, as opposed to the 3-5 day turnaround time of current methods. This...
Astek Diagnostics Inc. received a $255,975 Project Grant award from the National Science Foundation Division of Industrial Innovation on December 15, 2021 to support work completing August 31, 2022. The grant funds the development of rapid detection methods and determination of antibiotic resistance for blood-borne bacteria under the NSF Engineering program (CFDA 47.041). The Engineering program seeks to improve quality of life and economic strength by fostering innovation in engineering...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to the University of California, Los Angeles (UCLA) to design and develop a rapid phenotypic drug susceptibility test, termed TRE-DST, for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to specifically detect live Mycobacterium tuberculosis (MTB) and determine drug...